Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:.
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:.
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance1 of $43.2 million as of June 30, 2022; Restated Q1/22: Net. | November 7, 2022
Financial update: Q2/22: Net revenues of $18.3 million; Operating loss of $9.2 million; Cash balance[1] of $43.2 million as of June 30, 2022; Restated Q1/22:.
Talicia s efficacy, in this analysis of pooled data from two Phase 3 studies, was unaffected by presence of diabetes or elevated body mass index (BMI);.